Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people. Indeed, addiction (alcohol, tobacco, gambling...) is becoming a serious socio-economic problem and the US market for treatment of these pathologies reached $3 billion in 2013. Nevertheless, few therapeutic agents are available and efficient on these pathologies of addiction, to date.

KT-110 is the first project to enter phase 2 clinical trial based on this new strategy. KT-110, a patented composition, associates two off-patent drugs demonstrating a synergistic effect on addiction.

The proof of concept of KT-110 on alcohol addiction is planed for 2017-2019.